MedTrace Logo

Latanoprost for the Treatment of Menière's Disease

NCT01973114 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2016-03-23

No results posted yet for this study

Summary

The purpose of the study is to evaluate the dose regimen, efficacy and safety of latanoprost for the treatment of Menière's disease.

Conditions

  • Menière's Disease

Interventions

DRUG

Latanoprost

OTHER

Placebo

Sponsors & Collaborators

  • Synphora AB

    lead INDUSTRY

Principal Investigators

  • Mikael Karlberg, MD, PhD · Lund University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2016-05-31

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01973114 on ClinicalTrials.gov